All In MedTech

Device Trial Radar · NCT04770285

Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder

A Multi-center, Randomized, Controlled Trial to Evaluate the Effectiveness of a Digital Therapeutic (CT-152) as Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 386 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

386

Actual

Start

Feb 25, 2021

Primary completion

Oct 26, 2022

Study completion Oct 26, 2022

Sponsor

Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Click Therapeutics, Inc.
First posted
Feb 25, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the effectiveness of 2 digital therapeutics in adult participants diagnosed with major depressive disorder (MDD) who are on antidepressant therapy (ADT) monotherapy for the treatment of depression.

Conditions

  • Major Depressive Disorder

Interventions

  • CT-152 - Digital TherapeuticDevice

    CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.

  • ShamDevice

    Sham mobile app was used by the participants as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 6 in the MADRS Total ScoreTime frame: Baseline (Day 1) to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding sites, contact 844-687-8522

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.